Board of Directors

Eric Bednarski, Ph.D.Chairman
Dr. Bednarski is a partner at MVM Life Sciences, a venture capital firm that invests in technologies and products for the life science and healthcare markets, with over $500 million under management. He joined MVM in 2008 from Advent International in Boston where he was involved in several healthcare investments. Prior to Advent, Dr. Bednarski served as a director in the corporate finance group of Silicon Valley Bank. He previously worked in the drug discovery group of Dupont-Merck Pharmaceuticals. Dr. Bednarski holds a Ph.D. in neurobiology from the University of California and a B.S. from Brown University.
David BrandPresident, Founder & Chief Executive Officer, Director
Mr. Brand has more than three decades of pharmaceutical industry experience. Prior to Tarsa, he served as CEO and president of Cardiokine, where he led strategic and organizational development and negotiated a significant global agreement with Biogen Idec for late stage development and marketing of lixivaptan. Previously, Mr. Brand spent over 30 years at GlaxoSmithKline and its predecessor companies. Most recently, he headed the U.S. GI/CNS, product development, metabolic and cardiovascular business units, leading the U.S. launches of Paxil®, Requip® and Avandia®, the pre-launch development of Coreg®, Kytril® and Augmentin® ES/XR, and many co-marketing and licensing deals. Earlier, Mr. Brand held international senior management positions in marketing, acquisitions, business development and regional country management. He holds a bachelor of commerce degree from Concordia University in Montreal.
Martin Edwards, M.D.Director
Dr. Edwards is a senior partner at Novo A/S, a global life science venture capital firm that invests more than $100 million annually. Prior to Novo, Dr. Edwards served as CEO of ReNeuron Holdings, taking the company public in 2000. Earlier, he was corporate vice president and head of drug development for Novo Nordisk A/S. Previously, he served as senior vice president for medical affairs at Novo Nordisk and as vice president of pharmacology and medical affairs of ZymoGenetics. Dr. Edwards currently serves as a director of several life sciences firms and is chairman of Symphogen A/S. He holds degrees in physiology and medicine from Manchester University, as well as post graduate medical diplomas from the London Royal Colleges and an M.B.A. from Warwick University. Dr. Edwards is also adjunct professor of management at the Scandinavian Management Institute (SIMI) in Copenhagen and Copenhagen Business School (CBS).
Richard S. KollenderDirector
Mr. Kollender is a partner at Quaker Partners, a venture capital and growth equity firm investing in healthcare companies.  Previously, he worked at GlaxoSmithKline (GSK), where he held positions of increasing responsibility in sales, marketing and worldwide business development. Mr. Kollender also served as an investment manager at S.R. One, the venture unit of GSK.  He began his career as a certified public accountant with KPMG Peat Marwick and spent six years in public practice, which included an emphasis on healthcare and emerging businesses.  Mr. Kollender serves on the boards of directors of Rapid Micro Biosystems, Celator Pharmaceuticals (Nasdaq: CPXX) and Corridor Pharmaceuticals, and is a board observer for several other Quaker portfolio companies. He holds a B.A. from Franklin and Marshall College and an M.B.A. and Health Administration & Policy degrees with Honors from the University of Chicago.